Cancer's genetic heterogeneity presents a significant challenge to personalized medicine. While genomic sequencing identifies driver mutations underpinning tumorigenesis, translating this knowledge into effective therapies faces hurdles.  Firstly, identifying the crucial subset of mutations driving a specific cancer, amidst the backdrop of passenger mutations, requires sophisticated bioinformatics and robust validation.  Secondly, functional assays to assess the impact of identified mutations on drug response remain complex and often limited to in vitro models, which may poorly reflect the in vivo tumor microenvironment.  Thirdly, inter-tumoral and intratumoral heterogeneity necessitates longitudinal monitoring of clonal evolution, presenting logistical and technological difficulties.  Furthermore, the cost and accessibility of comprehensive genomic profiling pose barriers to widespread implementation.  Finally, integrating genomic data with other patient-specific factors like immune status and lifestyle remains a significant challenge in developing truly personalized treatment strategies. Overcoming these experimental limitations is crucial for realizing the full potential of personalized cancer medicine.